Brazil's President Eases Compulsory Licensing Law On Pandemic-Related Products
Executive Summary
Companies in Brazil will not have to provide know-how and other detailed information on patents that are subject to compulsory licenses during national or international emergencies, although other provisions of a law passed last year to ease the compulsory licensing process remain in place.
You may also be interested in...
EU Health Chief Under Pressure To Explain Delay In Legislative Overhaul
The latest delay to the European Commission’s proposals for revising the EU medicines legislation has caused consternation among members of the European Parliament who do not believe that the hold-up is due simply to a “busy agenda” at the commission.
NICE Confirms English Funding For Three COVID-19 Drugs, But Rejects Four Others
There is good news for medicines from Pfizer, GSK and Roche, but MSD, Gilead and AstraZeneca have all appealed against NICE’s decision not to recommend their products for treating COVID-19.
EU Sets New Date For Publication Of Delayed Pharma Revision Proposals
Lengthy legislative procedures are expected after the commission publishes its “pharma package” and the “patent package,” which are now due towards the end of April.